Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced at its investor day in Sydney today the introduction of the F&P Pilairo™ Q nasal pillows mask for the treatment of obstructive sleep apnea (OSA).
The Pilairo Q has been designed with a focus on quietness and versatility and retains the unique advantages customers have come to appreciate with the Pilairo. These include the effective seal as a result of the unique air-pillow which self inflates with CPAP flow and the one-size-fits-most, adjustment-free, Stretchwise headgear.
In addition, the Pilairo Q offers ultra-quiet use and minimal draft to eliminate any partner disturbance. Users also now have a choice of headgear, with the addition of an alternative, adjustable version that fits a wider range of patients.
“Pilairo has been very well received by customers and Pilairo Q builds on that success to provide additional options and benefits that enhance overall therapy performance including quieter use, less draft and a greater range of fit” commented Michael Daniell, Fisher & Paykel Healthcare’s Chief Executive Officer.
The Pilairo Q nasal pillows mask will be introduced to Australia, Canada and the United States in the coming weeks. “Pilairo Q further strengthens our premium mask offering, which includes the recently launched Eson nasal mask, and Simplus full face mask, both of which have performed exceptionally well for our customers”, concluded Mr Daniell.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company visit www.fphcare.com.
Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay, CFO on +64 9 574 0119. For more information about the company visit www.fphcare.com.